Protective effects of intracerebral adenoviral-mediated GDNF gene transfer in a rat model of Parkinson's disease

Parkinsonism and Related Disorders

Volumn 10, Issue 1, 2003, Pages 1-7

  Chen, Xianwen ^a   Liu, Weiguo ^a   Guoyuan, Yang ^b   Liu, Zhenguo ^a   Smith, Stuart ^c   Calne, Donald B ^d   Chen, Shengdi ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

6 Hydroxydopamine; Adeno virus; Dopamine neuron; Gene therapy; Glial cell line derived neurotrophic factor; Parkinson's disease

Indexed keywords

ADENOVIRUS VECTOR; APOMORPHINE; BRAIN MONOAMINE; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN LEVEL; CELL COUNT; CELL PROTECTION; CELL STRUCTURE; CELL SURVIVAL; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DRUG EFFECT; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

EID: 0141788689     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(03)00097-X     Document Type: Article

References (25)

1. Chauhan N.B., Lee J.M., Siegel G.J. Selective depletion of glial cell line-derived neurotrophic factor (GDNF) in Parkinson's disease. Neurology. 52:(6):1999;A212-A213. Supplement 2.
2. Lin L.F., Doherty D.H., Lile J.D., et al. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260:1993;1130-1132.
3. Tomac A., Lindqvist E., Lin L.F., et al. Protection and repair of the nigrostrital dopaminergic system by GDNF in vivo. Nature. 373:1995;335-339.
4. Kearns C.M., Gash D.M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672:1995;104-111.
5. Cass W.A. GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. J Neurosci. 16:1996;8132-8139.
6. Gash D.M., Zhang Z., Ovadia A., et al. Functional recovery in GDNF treated Parkinsonian monkeys. Nature. 380:1996;252-255.
7. Wood M.J., Charlton H.M., Wood K.J., et al. Immune responses to adenovirus vectors in the nervous system. Trends Neurosci. 19:1996;497-501.
8. Kajiwara K., Byrnes A.P., Charlton H.M., et al. Immune responses to adenoviral vectors during gene transfer in the brain. Hum Gene Ther. 8:1997;253-265.
9. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol. 158:1992;97-129.
10. Deglon N., Tseng J.L., Bensadoun J.C., et al. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Ther. 11:2000;179-190.
11. Nutt J.G., Bronstein J.M., Carter J.H., Jankovic J. Intraventricular administration of GDNF in the treatment of Parkinson's disease. Neurology. 56:(Suppl 3):2001;A375.
12. Kordower J.H., Emborg M.E., Bloch J., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 290:2000;767-773.
13. Sauer H., Oertlel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-OHDA: a combined retrograde tracing and immunocytochemical study in rat. Neuroscience. 59:1994;401-415.
14. Hudson J.L., Van Horne C.G., Stromberg I., et al. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 626:1993;167-174.
15. Bilang-Bleuel A., Revah F., Colin P., et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA. 94:(16):1997;8818-8823.
16. Kirik D., Rosenblad C., Bjorklund A., Mandel R. Long-term, rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci. 20:2000;4686-4700.
17. Rosenblad C., Martinez-Serrano A., Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience. 82:1998;129-137.
18. Shults C.W., Kimber T., Martin D. Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine. Neuroreport. 7:1996;627-631.
19. Bjorklund A., Kirik D., Rosenblad C., et al. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 886:(1/2):2000;82-98.
20. Sauer H., Rosenblad C., Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta-3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci USA. 92:1995;8935-8939.
21. Winkler C., Sauer H., Lee C.S., Bjorklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci. 16:1996;7206-7215.
22. Byrnes A.P., MacLaren R.E., Charlton H.M. Immunological instability of persistent adenovirus in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J Neurosci. 16:1996;3045-3055.
23. Hardy S., Kitamura M., Harris-Stansil T., et al. Construction of adenovirus vectors through Cre-lox recombination. J Virol. 71:1997;1842-1849.
24. Morral N., O'Neal W., Rice K., et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA. 96:1999;12816-12821.
25. Sandig V., Youil R., Bett A.J., et al. Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci USA. 97:2000;1002-1007.